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Abstract: This review evaluates the current surgical options for the management of idiopathic 
macular holes (IMHs), including vitrectomy, ocriplasmin (OCP), and expansile gas use, and 
discusses key background information to inform the choice of treatment. An evidence-based 
approach to selecting the best treatment option for the individual patient based on IMH charac-
teristics and patient-specific factors is suggested. For holes without vitreomacular attachment 
(VMA), vitrectomy is the only option with three key surgical variables: whether to peel the 
inner limiting membrane (ILM), the type of tamponade agent to be used, and the requirement 
for postoperative face-down posturing. There is a general consensus that ILM peeling improves 
primary anatomical hole closure rate; however, in small holes (250 µm), it is uncertain whether 
peeling is always required. It has been increasingly recognized that long-acting gas and face-
down positioning are not always necessary in patients with small- and medium-sized holes, but 
large (400 µm) and chronic holes (1-year history) are usually treated with long-acting gas 
and posturing. Several studies on posturing and gas choice were carried out in combination with 
ILM peeling, which may also influence the gas and posturing requirement. Combined phacovit-
rectomy appears to offer more rapid visual recovery without affecting the long-term outcomes 
of vitrectomy for IMH. OCP is licensed for use in patients with small- or medium-sized holes 
and VMA. A greater success rate in using OCP has been reported in smaller holes, but further 
predictive factors for its success are needed to refine its use. It is important to counsel patients 
realistically regarding the rates of success with intravitreal OCP and its potential complications. 
Expansile gas can be considered as a further option in small holes with VMA; however, larger 
studies are required to provide guidance on its use.
Keywords: ocriplasmin, vitrectomy, inner limiting membrane peel, posturing, tamponade 
agent, expansile gas
Introduction
The prevalence of idiopathic macular holes (IMHs) in the general population is 
estimated to be ∼3.3 per 1,000 people.1,2 It usually affects individuals in their sixth or 
seventh decade of life, and approximately two-thirds are females.1,3–5 Until 1991, it was 
considered an untreatable condition, but now interventions are routinely carried out to 
close the hole and thereby improve the central visual defect. Initially, vitrectomy sur-
gery with long-acting gas and postoperative face-down positioning for at least 1 week 
was the only option; however, nowadays, the surgeon and the patient have a number 
of possible treatment choices to select from. This review discusses these options and 
attempts to provide an evidence-based guide to aid decision making. First, we discuss 
some common features of IMHs, including their classification, progression, and fel-
low eye risk relevant to decision making. We then review the surgical options during 
vitrectomy surgery, followed by the new option of ocriplasmin (OCP) treatment and 
the more recent interest in intravitreal expansile gas injection. Finally, we suggest a 
pragmatic approach to choosing the optimum treatment in an individual case. The 
review confines itself to IMH and primary surgery.
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There is a general consensus that vitreous traction plays 
an important role in macular hole formation.6 Johnson and 
Gass published a seminal article on its pathogenesis in 
1988, in which they described the findings from careful slit 
lamp biomicroscopic examination of 158 eyes.7 Although 
now superseded with a greater insight into the pathogenesis 
provided by spectral domain optical coherence tomography 
(SD-OCT), it is still important to be aware of their findings. 
They described the earliest sign, during the evolution of 
IMH, as the presence of a yellowish foveal spot associated 
with flattening of the normal anatomic foveal depression 
(Stage 1A), which progressed into a yellow halo with a 
thinned reddish center (Stage 1B). This then enlarged into 
an early IMH (Stage 2), which could be either central or 
pericentric. If a vitreofoveal separation developed, this was 
termed Stage 3 and was detected by the presence of a sus-
pended operculum anterior to the retinal plane. If the vitreous 
subsequently completely separated from the optic disc with 
the presence of a Weiss ring, they termed this as Stage 4. 
A size threshold of 400 µm was subsequently applied to 
distinguish stage 3 from Stage 4 holes.8 The original Gass 
classification is still widely quoted, but SD-OCT-based clas-
sification systems provide a more consistent nomenclature 
for diagnosis, monitoring, and surgical decision making 
in vitreomacular interface diseases (Table 1 and Figures 1 
and 2). Perifoveal vitreous separation with persistent attach-
ment and localized traction on the foveolar identified on 
SD-OCT is now known to be the major etiological factor in 
most IMH cases.9 The International Vitreomacular Traction 
Study (IVTS) Group developed an OCT-based anatomic 
classification of vitreomacular interface diseases in 2013.10 
IMHs were subdivided by cause into primary (formerly 
referred to as idiopathic) or secondary and by the presence 
or absence of vitreous attachment. They were also classified 
into small (250 µm), medium (250 µm and 400 µm), 
and large (400 µm) based on the horizontally measured 
linear width at the narrowest point of the hole. More recently, 
a detailed classification of focal vitreomacular attachment 
(VMA) and traction (which includes Stage 1 macular holes) 
has been described with the acronym WISPERR (Width 
of vitreoretinal [VR] attachment, vitreoretinal Interface 
changes, Shape, Pigment epithelial changes, Elevation, and 
inner and outer Retinal changes).11
Gass Stage 4 is not separately covered by the IVTS clas-
sification. Stage 4 holes can be of any size and are defined 
by the presence of VR separation from the optic disk and 
fovea. Their significance relates to their likely chronicity 
and the extent of epiretinal vitreous and cellular remnants 
on the internal limiting surface (inner limiting membrane 
[ILM]) surface around the hole: Schumann et al found that 
extensive fibrocellular proliferation at the vitreal side of the 
ILM was seen more frequently in Stage 4 than in Stage 3 
holes.12 They proposed that in eyes with spontaneous vitreous 
separation, remnants of the vitreous often remain attached to 
the ILM. Similarly, Steel et al found an incomplete staining 
pattern with Brilliant Blue G (BBG) dye, signifying residual 
vitreous material on the ILM confirmed histologically in 
89% of patients with Stage 4 holes compared to only 24% 
of Stage 2 holes with VMA.13 Therefore, Gass Stage 4 holes 
generally require ILM peeling to achieve closure, regardless 
of the hole width.
Presentation grade
The case mix of patients with IMH presenting to a surgeon 
will vary by a range of factors, including the health care sys-
tem and referral pathways. In a study in the UK, out of 106 
eyes with IMH that underwent surgery by one surgeon, 36 
were small, 40 were medium, and 30 were large. As shown 
in Table 2, 28% were initially 400 µm in diameter with 
VMA.14 In a similar study in Israel, only 6.7% were of the 
same stage at presentation.15
Table 1 Comparison of the Gass and IVTS group classifications
Gass stages in common use Gass or Gass-derived classification IVTS classification equivalent
0 vMA in the fellow eye of a patient with a  
known/previous iMH without any change  
in foveal architecture
vMA
1 impending macular hole with outer retinal 
elevation from RPe at foveal center 
vMT without iMH: can occur with outer 
or inner retinal changes or both
2 400 µm iMH with vMA Small- or medium-sized iMH with vMT
3 400 µm iMH without vMA Large iMH without vMT
4 iMH with complete vitreous separation  
including from optic disk
Not classified separately could be either 
small, medium, or large iMH without vMT
Abbreviations: ivTS, international vitreomacular Traction Study; vMA, vitreomacular attachment; iMH, idiopathic macular hole; vMT, vitreomacular traction; RPe, retinal 
pigment epithelium.
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Measurements
SD-OCT allows precise measurement of IMH dimensions 
allowing accurate staging and assisting in surgical decision 
making.16 Dense scanning protocols are needed to capture the 
true hole dimensions accurately. Currently available devices 
have a transverse image resolution of between 10 µm and 
25 µm. The use of a real-time eye tracking system with precise 
multiple B-scan averaging reduces speckle noise artifact and 
results in very high repeatability and reproducibility.17,18
Several methods of IMH measurements using OCT 
scans have been described, including base diameter (BD) 
and minimum linear diameter (MLD), and the derived 
parameters, hole form factor, macular hole index, and trac-
tional hole index.19,20 Studies have shown that there is no real 
advantage in terms of predicting prognosis by calculating 
derived indices from the basic ophthalmic measurements.21 
The preoperative BD is easy to measure and is strongly 
associated with anatomical and visual outcomes.21 This 
Figure 1 SD-OCT images of Stage 1 holes.
Notes: (A) Focal vMA without traction (Grade 0). (B) vMT with inner retinal changes, (C) vMT with outer retinal changes, (D) vMT with outer retinal changes, and (E) 
vMT with inner and outer retinal changes.
Abbreviations: SD-OCT, spectral-domain optical coherence tomography; vMA, vitreomacular traction; vMT, vitreomacular traction.





finding seems rational, as BD is the linear dimension of IMH 
at the level of the retinal pigment epithelium layer, which 
is a reflection of the basic lesion being treated. However, 
MLD, which is defined as the minimum horizontal diam-
eter in the scan with the widest hole dimensions, is more 
commonly used. It is important to select an accurate OCT 
image that represents the true extent of the hole with its 
maximum dimensions when measuring the MLD without 
involving the operculated component of a hole with VMA 
(Figure 3).
Progression and fellow eyes
The limited natural history data available indicate that in a 
small percentage of cases, IMHs, especially small ones and 
those with vitreomacular traction (VMT), may close spon-
taneously. The reported incidence of such spontaneously 
closing IMHs in the literature is 2.7% to 8.6%.22–24
Sometimes patients are seen with small (50–100 µm) 
full-thickness macular holes without VMA, which are 
termed macular microholes.25 Johnson reported a high rate 
Figure 2 SD-OCT images of macular holes at different stages.
Notes: Left, fundus photography; right corresponding SD-OCT section, green line corresponds with level of OCT image, (A) Small iMH with vMA. (B) Small iMH with 
operculum vMA. (C) Large iMH with operculum and without vMT. (D) Large iMH with complete vitreous separation (Gass Stage 4).
Abbreviations: SD-OCT, spectral-domain optical coherence tomography; iMH, idiopathic macular hole; vMA, vitreomacular attachment; vMT, vitreomacular traction.
Table 2 Case mix of macular holes presenting to a UK eye unit 
over a 1-year period14
Size VMA (%) No VMA (%) Total (%)
Small 17 (16) 19 (18) 36 (34)
Medium 13 (12) 27 (25.5) 40 (38)
Large 3 (3) 27 (25.5) 30 (28)
Total 33 (31) 73 (69) 106 (100)
Note: Reproduced with permission from Karger © 2015, S. Karger AG. Madi HA, 
Dinah C, Rees J, et al. The case mix of patients presenting with full-thickness macular 
holes and progression before surgery: implications for optimum management. 
Ophthalmologica. 2015;233(3–4):216–221.14
Abbreviation: vMA, vitreomacular attachment.
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of spontaneous resolution of these holes within weeks, albeit 
often with a residual defect in the photoreceptor layer.26 
Presumably, they represent small holes with recent VMA 
separation and are in the process of closing when first seen. 
However, holes usually progress, and studies have shown a 
21.7%–77% increase in hole size over 6 years of follow-up, 
up to 400–600 µm, although larger holes are also seen.1,24,27,28 
In some studies, progression to Stage 3 or 4 holes has been 
reported to occur as early as 3 months after onset.3,7
The reported rate of development of macular holes in 
fellow eyes is variable, with an overall risk of 5%–10% over 
5 years.24,29,30 A fellow eye with complete VR separation at 
the fovea appears to have a very low risk (1%) of progress-
ing to an IMH.31 In fellow eyes with VR attachment, the 
risk of progression to full-thickness macular hole is broadly 
related to the extent of findings on the OCT, although figures 
available from the literature are very variable. Eyes with no 
VR separation anywhere on the OCT have a lower risk of 
progression.32 Eyes with focal VMA but no change in foveal 
profile (termed as Stage 0 if in a fellow eye) have a rate of 
progression ranging from 3.8% to 42%,31,33 with higher rates 
of evolution to IMH progressively observed in the following 
order: those with inner retinal cystic change  outer retinal 
change with focal foveal dehiscence  both inner and 
outer retinal changes (22%–55.6%).29,32–35 A randomized 
controlled trial (RCT) was conducted in the pre-OCT era, 
in 1994, to study whether intervention with vitrectomy at 
Stage 1 could prevent the formation of IMH. The trial was 
terminated early because of recruitment problems, but out 
of 62 recruited patients, 37% in the vitrectomy group and 
40% in the observation arm developed a full-thickness hole.36 
Despite the risk of progression, there is also a high rate of 
resolution with spontaneous VR separation, and hence, unless 
symptoms are significant and/or prolonged, most surgeons 
advise observation initially unless IMH occurs.
Recently, there has been a debate as to the importance 
of tangential VR traction in the progression of macular 
holes once they form. The tangential separation of the outer 
retina as the macular hole enlarges is much greater than the 
tangential separation of the inner retinal layers. A bistable 
hypothesis of macular hole formation has been proposed to 
explain this phenomenon based on the “z”-shaped configura-
tion of the Muller cells at the fovea.37
IMH characteristics can change very significantly 
in as short as a few weeks’ time, and if there is any gap 
between assessment and surgery, OCT assessment should 
Figure 3 Hole measurements (top), minimum linear diameter (MLD), and base diameter (BD) measurements.
Notes: The MLD is the minimum horizontal linear diameter in an area excluding the operculum and can be in the outer (left) or inner retina (right).





be repeated immediately prior to the intervention to select 
the optimum management.14
General prognostic factors for 
treatment
Numerous studies have identified predictors for successful 
IMH surgery, among which preoperative visual acuity is the 
most important. In general, eyes with better preoperative acuity 
achieve higher rates of anatomical closure and visual gain.38,39 
Smaller preoperative MLD and BD measurements are associ-
ated with better visual outcomes.20,21,39 Closure rates were found 
to be higher in patients with a shorter duration of symptoms and 
these patients similarly achieved better visual outcomes.40
Vitrectomy
IMHs had been considered untreatable until 1991, when Kelly 
and Wendel reported the first successful closure of a macular 
hole in 30 out of 52 (58%) patients with IMH using vitrectomy 
and gas.41 Subsequent to their publication, there was a rapid 
adoption of this basic technique, and it is now one of the com-
monest VR surgeries performed and accounted for 10% of all 
VR interventions performed in the UK from 2002 to 2010.4
Success rates in terms of closure of IMH with vitrectomy 
are now generally very high in the range of 85%–100%, 
depending on a number of prognostic predictors as mentioned 
above.21 In a recent analysis from a multicenter database 
study of real-world practice in the UK on a total of 1,045 
patients, 48.6% achieved visual success at 12 weeks post-
operatively (defined as 0.3 logarithm of minimal angle 
resolution [logMAR] units improvement); this proportion 
increased to 58.3% at 52 weeks, while 8% had deteriorated 
by 0.30  logMAR units. There is less evidence regarding 
changes in the quality of life following vitrectomy for IMH. 
However, in one study involving 45 patients, at 1 year fol-
lowing pars plana vitrectomy (PPV), statistically significant 
improvements in general vision, peripheral vision, near and 
distance activities, social functioning, mental health, and 
dependency were reported.42
Kelly and Wendel based the rationale for their surgery 
on Gass’s observation of macular hole formation and pos-
tulated that vitrectomy would remove traction around the 
hole and this, combined with gas tamponade, would result 
in the ring of perifoveal detachment flattening with some 
improvement in vision. Their technique fortunately resulted 
in hole apposition and closure in many patients with very 
significantly improved vision. In the concluding paragraph 
of their publication, they pointed out that although 58% 
of the patients had improved vision, 42% had persistently 
open holes, and encouraged further investigation into 
refinements that would improve the results and reduce the 
complications. Indeed during the intervening years, several 
variations and additions to the initial technique have been 
introduced with the aim of improving outcomes and safety. 
These include:
1. Tamponade type and posturing requirements;
2. ILM peeling;
3. combined lens surgery;
4. surgical adjuncts;
5. other advances in surgical technology and techniques.
Thus, a surgeon has a number of choices to select the 
operation he or she would perform on any individual patient 
with IMH. These choices are dependent to varying degrees on 
the characteristics of the IMH and will be discussed later.
Gas type and tamponade
After completion of vitrectomy and ILM peeling, fluid–air 
exchange is carried out with subsequent gas exchange, as 
originally described.41 Vitrectomy and posterior hyaloid 
face (PHF) separation act by removing the traction that is 
hypothesized to be causative. Gas tamponade is believed to 
additionally aid hole closure by:
•	 Bridging the hole thereby preventing trans-hole fluid 
flow from the vitreous cavity, allowing the retinal pig-
ment epithelium pump to remove the subretinal fluid, and 
also reducing trans-retinal uveal–scleral outflow with the 
resultant reduced retinal edema.
•	 Creating interfacial surface tension forces between the 
gas bubble and the retina acting to pull the edges of the 
hole together.43
•	 Acting as a surface to allow glial cell migration to bridge 
the gap between the retinal edges.44,45
The “buoyant force” of a gas bubble on a macular hole 
in the face-down position is thought to be less important 
(at least if all tangential force has been removed): it is the 
bridging of the gap that is the principal action.
Although Kelly and Wendel used sulfur hexafluoride 
(SF6) gas as a tamponade agent, when the procedure was 
subsequently adopted, most surgeons initially chose to use 
long-acting gas (C3F8) to maintain hole closure for as long 
as possible in an attempt to improve closure rates. Some 
surgeons have also used silicone oil for similar reasons. 
There has also been a dogma to position patients strictly 
face down for at least a week postoperatively to maximize 
tamponade apposition to the hole.46 However, there has been 
a gradual change in practice to increasing use of medium-
(C2F6) and short-acting gases (SF6 or air) and a reduction 
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in the duration and strictness of postoperative posturing 
requirements.20,47–50 Indeed, it has been increasingly recog-
nized that face-down positioning is not always necessary, 
particularly with smaller holes.21,51
There is a relationship between these two choices – gas 
choice and posturing requirement – that relates to the amount 
of time that the gas bridges the hole. Gas can still bridge the 
defect of a macular hole without face-down positioning in an 
upright position if the gas fill exceeds 50%, and long-acting 
tamponades will maintain 50% gas fill for a longer time 
than air or short-acting gases.
One of the problems with making this decision is that the pre-
cise time period that gas needs to bridge a macular hole to result 
in closure is uncertain. Indeed, the known closure of IMH with 
spontaneous vitreous separation and the recent demonstration 
that hole closure can occur with OCP alone show that tampon-
ade is not necessary at all in some holes. Preoperative macular 
hole size is the biggest single risk factor for surgical failure, and 
macular hole size appears to be a key factor dictating the type 
of gas used and the necessity to posture postoperatively.52 Hole 
chronicity is also important with likely reduced retinal compli-
ance resisting closure. Most authors have reported reduced rates 
of hole closure with holes 1 year duration.40,53
We briefly review some of the evidence behind choosing 
one tamponade over another and the importance of posturing 
and then summarize the decision-making process.
Gas choice
Surgeons use a variety of different isovolumetric gas concen-
trations at the end of surgery, but the total duration of gas fills 
is usually in the range of 2–2.5 weeks for SF6, 4–6 weeks 
for C2F6, and 8–11 weeks for C3F8. The resultant 50% fill 
times will be approximately half of these. Silicone oil will 
obviously maintain its size until removed.
SF6 versus C3F8
In 2008, a retrospective cohort study of 79 eyes with postop-
erative face-down positioning reported a closure rate of 90% 
with SF6 and 91% with C3F8.49 In a prospective randomized 
trial published in 2015, 59 eyes were randomized to either 
SF6 or C3F8 with differing posturing regimes and closure 
was achieved in 93.3% and 92.9%, respectively. Mean best-
corrected visual acuity improved by 17.7 letters in the SF6 
and 16.9 letters in the C3F8 group.54
SF6 versus C2F6
In a prospective cohort study of 78 patients undergoing 
surgery, 39 eyes treated with SF6 were compared with 39 
eyes treated with C2F6 both without face-down postur-
ing after surgery. Closure was achieved in 87% and 90%, 
respectively. At 6 months after the procedure, mean visual 
acuity improved from 0.78 logMAR to 0.38 logMAR in the 
SF6 group and from 0.81 logMAR to 0.44 logMAR in the 
C2F6 group.50
Air versus SF6
In 2008, a prospective study by Eckardt et al reported closure 
rates of 55% and 76% at 24 hours and 48 hours, respectively, 
following PPV surgery with room air tamponade and strict 
face-down positioning. Face-down positioning was stopped 
as soon as hole closure was confirmed on OCT.55
In 2009, a retrospective study of 156 eyes using either 
20% SF6 (91 eyes) or air (65 eyes) tamponade reported the 
primary hole closure rates of 90% and 92%, respectively. 
Face-down positioning was required for 7 days in the gas 
group and 4 days in the air group.56
Silicone oil versus C3F8
Silicone oil, both light and heavy, has also been used both as 
a tamponade agent and as a primary procedure.57,58
In a retrospective study published in 2003, Lai et al 
compared the outcomes using silicone oil (31 eyes) versus 
C3F8 gas (23 eyes) tamponade. Primary hole closure rates 
were 65% and 91%, respectively (P=0.022). The final median 
visual acuity values were 20/50 and 20/70, respectively 
(P=0.047).59
In a further retrospective study in 2005, 46 eyes with 
IMH received silicone oil tamponade (23 eyes) or C3F8 
tamponade (23 eyes). Anatomic closure occurred in 83% and 
87% of eyes, respectively. However, visual acuity improve-
ment to 20/70 or better was achieved in 17% in the oil group 
compared to 73% in the gas group.60
Posturing
Face-down positioning is uncomfortable for patients, occa-
sionally associated with a range of complications, includ-
ing back pain, sinusitis, and ulnar nerve palsies, and in 
some instances is unfeasible even with the aid of specially 
designed supports.55,61 Studies using OCT in the immediate 
postoperative period suggest that IMH occurs early in the 
postoperative course in most holes and hence one approach 
is to monitor daily for hole closure and stop face-down posi-
tioning when this occurs.55 Most surgeons are unable to do 
this; furthermore, hole opening can occur after initial closure, 
and hence standardized postoperative posturing instructions 
usually are given.62 However, several recent studies have 





suggested that face-down positioning is not necessary at all 
in some cases.
A recent Cochrane review analyzed data from three 
RCTs that directly compared face-down posturing follow-
ing IMH surgery with no face-down posturing.63–65 All the 
studies had quite different protocols other than posturing 
randomization. Guillaubey et al included 150 eyes and used 
ILM peeling and one of the three types of intraocular gases 
dependent on the size of the IMH (SF6, C2F6, or C3F8 gas 
for holes measuring 500 µm, 500–800 µm, and 800 µm, 
respectively).63 Tadayoni et al randomized 69 eyes with 
small- and medium-sized macular holes measuring 400 µm 
in diameter and used C2F6 gas for all the eyes, but ILM peel-
ing was not undertaken.66 Lange et al randomized 30 eyes 
and included ILM peeling and used C3F8 gas in all cases.64 
The authors of the Cochrane review tentatively concluded 
that for macular holes 400 µm, face-down posturing had 
no significant effect on successful hole closure. However, 
two of the studies found that there was a significant benefit 
of face-down posturing for successful closure when the 
diameter was 400 µm; this aspect is the subject of further 
ongoing RCTs.
Comment
It is possible that the results of nonposturing studies with 
long-acting tamponades may not apply to the use of short-
acting tamponade agents – so that if short-acting gases are 
used with medium-sized holes, posturing may still be ben-
eficial. Similarly, the duration of posturing is uncertain and 
has been variable in trials. The common recommendation is 
8 hours a day for at least 5–7 days.
Other considerations also come into play when choosing 
the tamponade type. The presence of gas tamponade in the 
vitreous cavity severely limits visual function. A one-eyed 
patient may therefore opt for air or SF6 tamponade to allow 
quicker visual recovery. Similarly, air travel may be a con-
sideration. Patients, if given a choice, may opt to do 5 days 
of posturing with air or a short-acting gas over nonposturing 
with a long-acting gas. Some patients may be unable to pos-
ture at all for various reasons, for whom long-acting gases 
would be the best option, especially in large holes.
The elimination of tangential traction is also important 
to achieve IMH closure. It is possible that holes with small 
degrees of persistent traction may still close if they are treated 
with prolonged gas tamponade as opposed to short-term 
tamponade. In addition, the small effect of the gas buoyant 
force with face-down posturing may be additive to overcome 
residual tangential forces. It is interesting that most of the 
aforementioned studies have used ILM peeling. Without 
ILM peeling, longer acting gases are probably more likely 
to result in closure.
Silicone oil seems to offer no advantages over the use 
of gas and has some possible disadvantages. Face-down 
posturing for at least 5 days postoperatively should be 
recommended for patients with macular holes 400 µm in 
size and holes 1 year in duration, until results of further 
RCTs are available.
iLM peeling
The removal of the ILM during MH surgery as a means to 
improve both anatomical and functional success was first 
described by Eckardt et al in 1997.67 Using ILM peeling, they 
described an anatomical success rate of 92% with an equally 
good functional success rate of 77%, and the procedure was 
quickly adopted.
Rationale
ILM peeling is believed to improve hole closure by:
•	 Increasing retinal compliance – the ILM despite being 
only a few microns thick contributes very significantly to 
retinal rigidity and also has a higher rigidity on the retinal 
side, accounting for its tendency to scroll upward when 
peeled. Its removal results in increased retinal compliance 
that aids closure.68
•	 Removing residual adherent vitreous cortex remnants on 
the ILM surface after PHF separation, which could exert 
persistent traction and prevent hole closure.
•	 Preventing the associated fibrocellular proliferation that 
has been shown to occur surrounding the hole and extend-
ing out onto the ILM surface in a significant number 
of cases – the ILM thus acts as a scaffold for cells to 
grow on.69
•	 Resulting in a retinal glial cell proliferation response that 
may paradoxically help IMH contraction and repair.44,68
Dyes to facilitate peeling
ILM peeling can be surgically challenging, and to facilitate 
its execution, various dyes have been introduced to help 
visualize this colorless thin membrane. Indocyanine green 
(ICG) was the first dye used in IMH surgery to stain ILM 
specifically in 2000.70 Subsequently, multiple reports debat-
ing the safety of ICG have been published. A wide variety 
of adverse effects have been described, including inner 
retinal changes,71 retinal pigment epithelium changes,72–74 
and optic disk atrophy with associated detrimental effects on 
visual acuity,72,74,75 visual field,74,76,77 and electroretinogram 
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changes.71,78 The concentration of ICG used is critical as 
are the application time and light exposure. ICG has known 
photosensitizing properties and its resultant decomposition 
products after illumination are believed to result in inner 
retinal toxic reactions, and it also results in large amounts of 
retinal side ILM cellular debris after peeling.76
Other dyes used for the same purpose include BBG, an 
ILM-specific dye; trypan blue, a vital dye that stains both 
ERM and ILM; and more recently Acid Violet 17.79 Par-
ticulate stains, such as triamcinolone, are also used that aid 
ILM identification during peeling by their physical presence 
on the peeled ILM. Both BBG and trypan blue appear to be 
safer dyes compared to ICG.78,80,81 Dyes heavier than water 
prepared by mixing with deuterium oxide, polyethylene gly-
col, or mannitol and avoiding the need for fluid–air exchange 
have been produced and are now in widespread use.13
Regardless of the dye used, the contact time, ie, the time 
that the dye is left on the retinal surface before being aspirated 
off, should be minimized, and contact times of 5–10 seconds 
can give adequate staining.13 ILM-specific dyes can also be 
used with this regime to assess the degree of fibrocellular 
material on the ILM, which could potentially be used to 
guide the extent or necessity of ILM peeling, especially in 
small holes.13
Technique and iLM peel size
Various techniques of ILM peeling have been described. 
Improved forceps design has allowed pinch peeling tech-
niques to be used, thus avoiding the need for the potentially 
damaging use of picks to raise an ILM edge. Diamond-dusted 
membrane scrapers (DDMSs) have also been used to initiate 
and peel the ILM, although use of a DDMS to peel ILM has 
recently been shown to be associated with a greater degree 
of appearance of a dissociated optic nerve fiber layer post-
operatively than that observed with forceps peeling with a 
deeper plane of retinal ILM separation.82 The extent of ILM 
peeled varies between surgeons, with no prescribed amount. 
A radius of peel of between 1.5- and 3-disk diameters has 
been described.83 Most surgeons peel with a 1- to 1.5-disk 
diameter radius, and wider areas are generally peeled in larger 
holes. Similarly, eyes that have persistent macular holes after 
surgery with ILM peeling can sometimes be closed if the ILM 
peel area is increased. D’Souza et al reported the results of 
30 patients who had unsuccessful anatomical closure after 
initial surgery with ILM peeling. They underwent enlarge-
ment of the ILM rhexis and gas tamponade with C3F8, and 
closure was achieved in 14 (47%) out of 30 eyes.84 A tech-
nique of using autologous ILM folded into the hole itself to 
improve closure rates in cases of large primary or persistent 
macular holes, termed as the inverted ILM flap technique, 
has been described.85
On the other hand, in the pursuit of minimizing ILM 
peeling-related complications, Ho et al have described a 
foveola-sparing ILM peeling technique for Stage 2 IMH.86 
Recently, a technique termed as ILM abrasion with a DDMS 
has been suggested as a suitable alternative to peeling, with 
high success rates.87
Side effects
Although ILM peeling has increased both anatomical and 
functional success rates, it can result in a number of seque-
lae. Various consequences have been described, including 
a characteristic dimpled appearance to the retina in the 
ILM-peeled area termed as a dissociated optic nerve fiber 
layer appearance,88,89 inner retinal defects,90 thinning of the 
ganglion cell complex,91 and migration of the fovea toward 
the disk after ILM peeling.92 Some authors have also reported 
functional deficits attributed to ILM peeling, including 
reduced retinal sensitivity and an increased incidence of peri-
foveal microscotomas, although no clear detrimental effect of 
ILM peeling on visual acuity has been demonstrated.93
evidence base for iLM peeling to improve closure 
rate
Several randomized studies have been carried out on the 
efficacy of ILM peeling in IMH surgery. In one large RCT, 
closure was achieved in 84% of the patients undergoing 
ILM peeling compared to 48% who did not undergo ILM 
peeling (P0.001) at 1 month postoperatively.83 A recent 
Cochrane review of four RCTs concluded that the avail-
able evidence supported ILM peeling in Stages 2, 3, and 
4 IMHs.94 However, it should be noted that some of these 
studies were without OCT measurements of the hole size, 
and the evidence base for peeling small IMHs is less robust, 
where the closure rate without ILM peeling can be high.95
Summary of evidence for tamponade 
type, posturing, and iLM peeling
There are thus three key variables to vitrectomy surgery for 
IMH: which gas to use, whether to recommend posturing, 
and whether to peel the ILM. Some surgeons use the same 
regime for all patients; others adjust the regime according 
to IMH characteristics and individual patient features (eg, 
inability to posture). Each of the three choices are partly 
dependent on each other as already mentioned (eg, nonpos-
turing surgery with air in medium/large holes without ILM 





peeling would likely have a low chance of success). Chronic 
macular holes 1 year in duration should probably be treated 
with ILM peeling and face-down positioning or at least longer 
acting gases in all cases. However, general recommendations 
are outlined in Table 3.
Combined phacovitrectomy versus 
sequential surgery
Cataracts are very common following vitrectomy, especially 
in the 60-year-old age group and when long-acting gases are 
used. Progression of existing cataracts in patients undergoing 
PPV for IMH has been reported to occur in 34% and 50% at 
6 months and 12 months follow-up, respectively.39,96
Combined phacovitrectomy has been widely adopted 
during macular hole surgery to avoid the need for subsequent 
cataract surgery.97 However, potential adverse effects of the 
procedure can be a higher incidence of posterior synechiae 
formation, posterior capsule opacity, intraocular lens-related 
complications, and a small (∼0.5 diopter) myopic shift in 
refraction.98,99 There is also the potential for cataract surgery-
related complications, for example, corneal edema, which 
could make the primary aims of the vitrectomy surgery, 
including ILM peeling, more challenging to achieve. Several 
surgical tips and techniques can reduce the occurrence of 
these problems (Table 4).
Conversely, sequential surgery has been associated 
with a higher rate of posterior capsule rupture and other 
operative difficulties during the subsequent cataract surgery, 
associated with the lens–iris diaphragm syndrome after 
vitrectomy.100,101
Combined phacovitrectomy has been compared with 
sequential vitrectomy and phacoemulsification, during the 
1st year following vitrectomy in 120 eyes with IMH and 
preexisting cataract.102 Best-corrected visual acuity improved 
significantly at 6 months after phacovitrectomy, with no sig-
nificant further improvement after this time. However, in the 
sequential procedure group, visual acuity improved only at 
the 1-year follow-up. IMH closure at 1 month after one sur-
gical procedure was 100% in the phacovitrectomy and 96% 
in the sequential vitrectomy and phacoemulsification group. 
There is no clear evidence that combined phacovitrectomy 
affects the long-term results of PPV for IMH, but the visual 
recovery is quicker.
Adjunctive agents to improve 
closure rate
The use of a variety of agents at the time of surgery has been 
described to improve closure rate. Smiddy et al described the use 
of transforming growth factor beta 2 as a chorioretinal adhesive 
to assist in the closure of the IMH.103 Autologous serum and 
platelets have also been used.104,105 Currently, other than a few 
exceptions, these agents are reserved for patients with chronic or 
large (650 µm) or nonclosure IMHs with initial surgery.106
Although outside the scope of this article, a variety of tech-
niques have been described in cases of primary nonclosure, 
including simple enlargement of the peeled ILM area. The use 
of heavy silicone oil has also been advocated with a reported 
87%–92% closure rate in these cases.57,107 A wide variety 
of other techniques have been reported, including ILM and 
capsular flaps, retinal relieving incisions, laser, mobilization 
of the edges of the hole, and drainage of chronic fluid from 
the center of the hole in cases of refractory holes.108–110
Other advances in surgical 
techniques and equipment
The most fundamental part of IMH surgery, namely PHF 
separation, has changed little since 1991. Aspiration is used to 
engage the PHF and then traction is exerted with an instrument 
movement anteriorly to strip the PHF from the retinal and optic 
disk surface. Surgeons generally start from the peripapillary 
area. Vitreous staining with particulate stains, including those 
based on triamcinolone and more recently lutein, has aided the 
visualization and hence the surgical ease of this phase.
Narrow-gauge vitrectomy surgery
In 1991, at the time of the first vitrectomy surgery for macu-
lar holes, 20 G surgery noncannulated sclerostomy systems 
were universally used. Since then, there have been a variety 
Table 3 Recommendations for iLM peeling, gas use, and posturing necessity
Size (MLD)/stage of hole 250 µm 250–400 µm 400 µm Stage 4 of any size
iLM peeling Uncertain if required in all cases Required Required Required regardless of size 
Posturing Not required Not required (particularly if long- 




if iLM peeled based on size 
of hole 
Long-acting gas Not required Not required Probably improves 
closure rates
if peeled based on size 
of hole 
Abbreviations: iLM, inner limiting membrane; MLD, minimum linear diameter.
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of advancements in the technology, including higher speed 
lower traction cutting, narrower gauge instrumentation with 
cannulated and valved entry systems, and improvements in 
intraoperative visualization with wide-field viewing and 
improved illumination. As a result, surgery has become safer 
and more efficient, thereby reducing perioperative compli-
cations such as iatrogenic retinal breaks and postoperative 
retinal detachment.
Narrow-gauge surgery has in particular been adopted 
widely, although with debate regarding its relative pros 
and cons (Table 5). Indeed, 27 G surgery has recently been 
introduced with an instrument diameter of ∼0.35 mm com-
pared to 20 G at 1.1 mm. However, there is no evidence that 
narrow-gauge surgery is more effective for macular hole 
surgery than 20 G in terms of visual outcome and closure 
although results appear comparable.111
In case series and reviews of patients undergoing 20 G 
conventional PPV, the reported incidence of iatrogenic 
peripheral retinal breaks has been variable, ranging from 6% 
to 36%.83,111,112 The reported rates of peripheral retinal break 
Table 4 Surgical tips for performing combined phacovitrectomy macular hole surgery
Surgical problem Surgical solution
Phacoemulsification wound leak if sclerostomy 
ports inserted after phacoemulsification has been 
carried out
Insert sclerostomy ports first prior to lens surgery. Use valved 
sclerostomies to avoid vitreous cavity volume loss and LiDRS 
precipitation
Corneal edema interfering with vitrectomy Use a temporal wound to maximize distance of wound from 
visual axis. Keep IOP moderate and practice efficient in the bag 
phacoemulsification with minimum power necessary
Miosis after phacoemulsification prior to vitrectomy Prevent hypotony at all times, maintain a deep anterior 
chamber and avoid any contact with iris. Use a suture to secure 
the wound if there is any leak at all after phacoemulsification 
prior to vitrectomy
Higher incidence of posterior capsule opacity Perform a small central primary posterior capsulotomy with the 
vitrectomy cutter
Higher risk of iOL optic capture or displacement Perform a central 5 mm maximum capsulorhexis to ensure the 
optic is held back and do not dilate the pupil after surgery for 
the 1st week. Use a large optic iOL ideally with plate style as 
opposed to single arm haptics
Posterior synechiae formation Avoid dilatation for 1st week and use subconjunctival and 
frequent topical steroids postoperatively. Avoid AC shallowing 
during vitrectomy with corneal suture if needed (see miosis) 
Abbreviations: LiDRS, lens–iris diaphragm retropulsion syndrome; iOP, intraocular pressure; iOL, intraocular lens; AC, anterior chamber.
Table 5 Pros and cons of conventional sutured 20 G vitrectomy versus narrow-gauge transconjunctival systems with cannulated 
sclerostomies
Pros Cons
20 G More rigid instruments
Availability of angulated scissors
Greater potential illumination
Higher achievable flow rates
Less prone to clogging with dense material
Sutures needed to close conjunctiva and sclerostomies 
with postoperative surface discomfort and irritation
Higher rate of sclerostomy related retinal breaks
Requirements for plugs to close sclerostomies when 
instruments removed from eye
Reduced globe stability with higher potential for surge
Narrow gauge Less conjunctival disruption and faster surface 
recovery with less postoperative discomfort
Quick entry and exit from eye
Less potential for entry site trauma and lower 
incidence of entry site associated retinal breaks
Lower flow rates with narrower field flow effects 
and less retinal traction
Smaller cutter port size with more precise end 
cutting ability
valved sclerostomies eliminate unwanted 
sclerostomy leak
Postoperative hypotony with sclerostomy leak in some 
cases
Change in technique needed to use less rigid instruments
Lower achievable flow rates
Occasional requirement to open conjunctiva and enlarge 
sclerostomy to introduce larger instruments
Lower infusion flow rates with higher resistance





formation appear to be lower with narrow-gauge surgery 
using cannulated sclerostomy systems with breaks reported 
in 11%–16% of procedures and only 3%−6% related to 
sclerostomies.111,113,114 Retinal detachment has been reported 
in ∼2%−6% of patients undergoing PPV for IMH.83,113–115 The 
rate is possibly lower with narrow-gauge surgery, but there 
is no evidence from an RCT.116 There is no difference in the 
rate of cataract formation between narrow-gauge vitrectomy 
and 20 G.117
Hypotony related to wound leakage is a concern with 
sutureless PPV, occurring in a reported 3%–16% of eyes.115,118 
In the majority of cases, this resolves spontaneously, and its 
incidence has been reducing as sclerostomy entry systems 
improve and gauge size reduces.
Endophthalmitis is very rare, occurring in 0.02%–0.05% 
of cases. Initially, narrow-gauge vitrectomy was believed to 
be associated with a higher incidence of endophthalmitis than 
20 G PPV; however, this has not proven to be true.119,120
Limited vitrectomy and PHF separation
Some authors have suggested limiting PHF separation to the 
macular area during surgery. Kim et al suggested that partial 
posterior hyaloidectomy, as they had termed it, could mini-
mize the traction on the vitreous base and therefore reduce 
the risk of iatrogenic retinal breaks.121 They reported a reduc-
tion in retinal break formation from 21% to 5% compared 
with conventional 23 G surgery, although they did note two 
postoperative retinal detachments in the modified technique 
group. Cullinane and Cleary also suggested a similar tech-
nique, but primarily to reduce the incidence of symptomatic 
field defects after surgery.122
Symptomatic peripheral field defects after vitrectomy 
for IMH have been the subject of a number of publica-
tions, although they are an uncommon finding (1% of 
procedures).123 These are usually temporal and possibly 
related to vitreous separation, particularly from the nasal 
side of the optic disk or alternatively from the consequences 
of air/fluid exchange and secondary desiccation of the nasal 
retinal surface.122,124 Various modifications of the technique 
have been reported including using air humidifiers for air/
fluid exchange, although it has not been the subject of many 
recent series.125 Cullinane and Cleary reported a reduction 
in the incidence of field defects from 22% to 0% with their 
technique, although the incidence of postoperative retinal 
detachment was 10% with the modified limited vitrectomy 
group technique compared to 3.6% in the conventional tech-
nique. Closure rates with both series of limited vitrectomy 
were similar to other reported cohorts.
Ocriplasmin
OCP has been recently approved for the nonsurgical treatment 
of symptomatic VMA, including when associated with IMH 
of 400 µm in minimum linear diameter.126 It is adminis-
tered by a single 0.1 mL of 125 µg intravitreal injection. It 
is a recombinant truncated form of human plasmin and has 
proteolytic activity against fibronectin and laminin, two major 
components of the VR interface.126–128 This action coupled 
with the activation of endogenous matrix metalloproteinase-2 
is believed to result in its ability to precipitate VR separa-
tion.129 By releasing VMA in cases with early IMH formation, 
it can result in hole closure in some patients.
Two multicenter, double-blinded, placebo-controlled 
Phase III trials on 652 patients provided pre-marketing 
clinical outcome data. Patients were randomized to OCP or 
an OCP vehicle injection without the drug as a control.126 
In total, 153 patients with IMH 400 µm with VMA were 
included in the studies with 106 patients in the OCP group 
and 47 in the placebo group. The trial excluded patients 
with high myopia (-8 diopters) from the study. Since the 
marketing of the drug, there have also been small series of 
real-world experience published.
Anatomical outcomes
IMH closure occurred in 43/106 (40.6%) of eyes in the OCP 
group compared with 5/47 (10.6%) in the placebo group 
(P0.001).126 Closure was evident by a month postinjec-
tion in all cases. In a subset analysis, 48 patients with small 
IMH showed a higher closure rate with OCP (58.3% versus 
16% with placebo, P0.001) compared to the 38 patients 
with medium-sized holes (36.8% versus 5.3% with placebo, 
P=0.009). None of the 19 patients included in the study 
against protocol with large holes achieved closure.
Interestingly in the Phase III trials, 19 out of 43 patients 
with OCP-induced IMH closure had not had VMA release 
by day 28 or month 6 meaning macular hole closure occurred 
without VMA release.130 This could be related to the drugs 
liquefactant effect or local vitreous separation around the 
VMA point.131
The proportion of patients with IMH reopening after 
FTMH closure was low: four of 43 (9%) patients in the 
OCP group.132
Overall, the recent published postmarketing experiences 
with OCP have reported a lower rate of IMH closure than 
the MIVI studies (Table 6). The rate of closure in small 
holes was 35% (10/29), medium holes was 19% (6/32), 
and large holes was 25% (1/4).131,133–140 The overall rate 
of closure in the post launch studies was 26% (17/65), in 
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contrast to the 40.6% rate achieved in the MIVI trials. The 
rate of VMA release was 33/61 (54%), indicating that in at 
least 16 cases OCP induced VR cleavage without resultant 
IMH closure.
visual acuity
For the patients with OCP-induced hole closure, 72% patients 
gained at least two lines of vision (10 letters) at month 6 
and 49% gained at least three lines of vision (15 letters) at 
month 6.132 Conversely in the 63 patients treated with OCP 
without hole closure, 14% lost at least two lines of vision 
and 11% lost at least three lines of vision by month 6. In 
the 42 patients without hole closure after vehicle injection, 
percentage declines were similar with 15% patients loosing 
at least two lines of vision and 12% loosing at least three 
lines of vision at month 6.
Macular hole formation/enlargement 
after OCP
The incidence of new or worsening IMH in the MIVI tri-
als was reported as 7% in OCP-treated arm and 10% in the 
vehicle-treated arm and although IMH can be induced in 
patients with VMT treated with OCP, this does not appear 
to be at much higher rate than after placebo or indeed pos-
sibly natural history.
In patients with unsuccessful nonsurgical IMH closure 
at day 28, the hole diameter increased from baseline in both 
groups but the increase was greater in the OCP versus the 
placebo group at all time points. This observation has been 
confirmed post marketing, and the increase in size is particu-
larly noticeable in BD (Figure 4).131 Indeed even in eyes with 
successful closure after OCP, it is quite common to observe 
the presence of subfoveal subretinal fluid with greater dimen-
sions than the original hole BD (Figure 5).137,139
visual outcomes in those with initial nonclosure
For the patients not achieving IMH closure after OCP or 
vehicle and who then underwent vitrectomy, the rates of 
IMH closure in both groups were high at 79% and 89%, 
respectively. Among the patients who required vitrectomy 
to achieve hole closure, 32% eyes had previously received 
OCP and 26% (P=0.622) had previously received vehicle 
gained at least two lines of vision. Both these results and 
subsequent studies have suggested no detrimental effect of 
OCP if it does not work and vitrectomy is required.131
Hager et al however detected abnormal subretinal fluid 
post vitrectomy following unsuccessful OCP use, which 
persisted for 7 months, although the hole remained closed 
and vision improved.137
Positive predictive factors for vMA 
release
In the Phase III trials, age 65 years, phakia, width of 
VMT 1,500 µm, and absence of ERM were identified as 
positive predictive factors for release of VMA but not specifi-
cally for IMH closure. Future studies with SD OCT might 
identify other factors predictive of IMH closure with OCP.
Adverse events
The Phase III trials concluded that OCP had an acceptable 
safety profile. The incidence of ocular adverse events (AEs) 
was similar in the OCP and control vehicle groups (77% and 
69%, respectively). The majority of AE that occurred in the 
OCP group were minor and related to its vitreolytic effects. 
These included floaters, photopsia, and transiently blurred 
vision.141 Indeed, it is common for patients treated with 
OCP to experience a snowstorm effect to their vision in the 
first 24–48 hours with usual complete resolution. However, 
various other more serious AEs have been described some 
Table 6 Summary of post marketing published series of iMH treated with OCP
IMH closure by size VMA release by size
250 µm 250–400 µm 400 µm 250 µm 250–400 µm 400 µm
Study 1133 1/2 1/4 0/1 1/2 1/4 0/1
Study 2134 2/6 1/3 1/1 6/6 2/3 1/1
Study 3135 2/6 2/8 0/1 2/6 4/8 0
Study 4136 0 0/2 0 0 0/2 0
Study 5137 0 0/2 0 0 0/2 0
Study 6138 1/3 0/3 0 3/6a 0
Study 7139 0 2/2 0/1 NR NR NR
Study 8140 1/6 0/2 0 6/8
Study 9131 3/6 0/6 0 5/6 2/6 0
Total (%) 10/29 (34.5) 6/32 (18.8) 1/4 (25) 61/62 (54)
Notes: aThe small iMH that closed had persistent vMA. in studies 138–140 vMA release data by hole size could not be extrapolated from published data.
Abbreviations: iMH, idiopathic macular hole; OCP, ocriplasmin; vMA, vitreomacular attachment; NR, not recorded.





Figure 4 SD-OCT image of a macular hole pre- and post-Ocriplasmin injection without closure.
Notes: Left, fundus photography; right, SD-OCT, green line corresponds with level of OCT image, (A) immediately pre-ocriplasmin (OCP) injection (note area of vMA was 
on edge of hole, not shown), (B) 1 week post OCP injection showing widened base diameter, and (C) following successful hole closure after vitrectomy and iLM peel.
Abbreviations: vMA, vitreomacular attachment; iLM, inner limiting membrane; OCP, ocriplasmin; SD-OCT, spectral-domain optical coherence tomography.
of which might be expected and related to increased traction 
as vitreous liquefies without VR release (increased VMT and 
MH formation) or conversely the adverse effects of vitreous 
separation (retinal tears and detachment). Conversely, some 
of the events reported were less expected including:
•	 Reduced vision with a variety of outer retinal changes 
including the development of subretinal fluid, ellipsoid 
zone changes, ERG changes, and dyschromatopsia;
•	 impaired pupillary reflex;
•	 retinal vessel changes;
•	 lens subluxation or phacodonesis.
Most of these were known from the Phase III trials but 
some have only been recognized since the product was mar-
keted. In particular, the higher resolution of SD OCT led to 
the recognition that changes in the ellipsoid zone can occur 
transiently with OCP. None of the AEs have been reported 
to be more frequent in eyes with IMH than VMT alone.
visual loss
Out of 465 patients treated with OCP in the Phase III trials, 36 
(8%) experienced an acute reduction in visual acuity with a 
mean letter loss of almost three lines.141 Most were attributed 
to either progression of the associated macular pathology 
(VMT and/or IMH) or to onset of a subretinal fluid at the 
fovea despite VMA resolution. The onset of subretinal fluid 
was initially attributed to increased traction prior to VMT 
release but has also been postulated to be related to the effect 
of OCP on laminin substrates in the outer retina.
Thirty of the 36 cases resolved by the 6-month study end 
point but visual loss in six patients (17% of patients with 
vision loss and 1.3% of total patients) persisted to study 
end at 6 months. Five of these six patients were reported 
to have reasons related to the pathology or vitrectomy 
complications but one of the six patients had vision loss for 
unknown reasons, despite VMA resolution and anatomical 
improvement.
Dyschromatopsia, eRG changes, and anatomically 
observed outer retinal changes
To go along with an effect of OCP on the outer retina, dys-
chromatopsia (usually described as yellow-tinted vision) was 
reported in 4% of patients treated with OCP in the Phase III 
studies. The symptoms resolved in 75% of the cases with a 
median time of 3 months. Many cases of dyschromatopsia 
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reported have also had ERG changes, and ERG changes have 
been described in other patients receiving OCP. They have 
principally been decreased in a- and b-wave amplitude. The 
incidence is uncertain but based on Phase II data may be as 
high as 70%, although many will be subclinical.
There have also been at least 36 reported cases in the 
literature of transient changes in the outer retinal layers on 
SD-OCT scans described as disruption/loss of the ellipsoid 
zone, and some associated transient visual loss.135,138–140,142 
The mean time to onset ranged from 5 days to 7 days. 
The changes in the majority of cases appear to resolve by 
2 months with a mean time in reported cases of 49 days; 
however in four reported cases, changes and symptoms 
have persisted throughout 6 months of follow-up.140 Interest-
ingly, these changes have been more common in eyes with 
successful VMA release and in some cases have also been 
associated with the transient accumulation of subretinal fluid 
in the macular area.
All four of these outer retinal effects have been postulated 
to be due to the action of OCP on laminin and hence retinal 
disruption at the photoreceptor level. Recovery presumably 
occurs through laminin restoration, although the long-term 
sequelae of this are uncertain.
Pupillary changes
Miosis, pupillary inequality, and impaired pupillary reflexes 
have all been reported 1–2 days post OCP with an incidence 
of 1%–2% and usual resolution within 3 days.
Lens subluxation or phacodonesis
In the premarketing trials, there were two cases of lens sub-
luxation or phacodonesis out of a total of 976 OCP-treated 
patients.141 After marketing, there have been further case 
reports and the effect is likely due to the action of OCP on 
the lens zonules.143 It is interesting to postulate that this is 
more likely with anterior intravitreal injection, and hence, 
deep mid cavity OCP injection is recommended away from 
the zonular area.
Retinal tears and detachment
Paradoxically the incidence of retinal breaks and detachments 
was lower in the OCP group than the placebo (1.9% versus 
Figure 5 SD-OCT image of a macular hole pre- and post-Ocriplasmin injection with successful hole closure.
Notes: Left, fundus photography; right, SD-OCT, green line corresponds with level of OCT image, (A) small hole with vMA pre-ocriplasmin injection (note the full-thickness 
defect was eccentric and shown in insert picture), (B) closure of hole 1 week post ocriplasmin with VMA release but note the presence of subfoveal subretinal fluid, and (C) 
resolution of subretinal fluid 3 months later.
Abbreviations: vMA, vitreomacular attachment; SD-OCT, spectral-domain optical coherence tomography.





4.3%, respectively) in the Phase III trials. In both groups, 
however, the majority of retinal tears and detachments were 
noted during or shortly after vitrectomy.
Since launch a further 17 cases (0.4%) of retinal tears 
and/or breaks have been reported separately from vitrectomy 
surgery as might be expected with the creation of vitreous 
separation. The mean time to onset of these cases has been 
reported as 20 days (range 8–68 days).132
Comment
OCP is a new treatment option for small- and medium-sized 
IMH with VMA, although its exact clinical role is an evolving 
story. Its price is greater than vitrectomy surgery in some health 
care systems. It is important to counsel patients realistically, 
regarding the rates of success with intravitreal OCP which 
are much lower than with vitrectomy surgery particularly in 
medium-sized holes. It should not be used in large holes. Fur-
ther factors predicting success in individual cases are needed 
to refine its optimum use. The incidence and characteristics 
of AEs have been generally similar between the premarketing 
and postmarketing periods, although more experience will 
be needed to assess the long-term morbidity in some patients 
particularly those with photoreceptor dysfunction and visual 
loss. In patients treated with OCP, careful monitoring and 
immediate evaluation of any symptomatic patient are para-
mount. Surgical treatment should not be delayed if closure 
does not occur by 4 weeks post OCP injection.
Pneumatic vitreolysis
Pneumatic vitreolysis was first described on animal models 
in 1984 by two groups lead by Thresher et al144 and Miller 
et al145. In 1995, Chan et al reported a series of 19 eyes with 
Stage 1–3 macular holes treated with injection of expansile 
gas bubble into the vitreous cavity to relieve vitreofoveal trac-
tion by inducing a PVD, which was achieved in 18 of 19 eyes 
within 2–9 weeks of treatment. Hole closure was achieved in 
three of the six Stage 2 IMH included but none of the Stage 3 
holes.146 In 2007, a comparable study by Mori et al reported 
results for treatment of Stage 2 macular holes with intravit-
real injection of SF6 gas bubble. PVD was achieved in 95% 
of eyes (19 of 20) with a 50% anatomical closure rate.147 In 
both series, no major complications were reported. In 2012, 
however a series by Chen et al of 12 patients with Stage 2 
MH only achieved a 50% vitreomacular separation rate and a 
25% hole closure rate. One case developed a rhegmatogenous 
retinal detachment.148 Jorge et al reported on six patients 
with Stage 2 IMH treated with expansile C3F8. Closure 
was achieved in five and VMT release in all.149 Overall of 
the full-thickness IMH treated in the abovementioned series, 
∼45% have closed comparable to the results with OCP.
Some of these series included postoperative prone 
positioning and some didn’t. Clearly, this is an area that 
requires further investigation with large controlled trials but 
reported results are encouraging.
Choosing the optimum 
management option
Thus, there are three current treatment choices for patients 
with IMH. The third, expansile gas has yet to undergo large 
scale RCTs and so no clear guidance can be given regarding 
its use. However, it is an option that could be considered in 
patients with small holes and VMA.
Of note, and applicable to all treatment choices is that 
macular hole characteristics can change in a short period of 
time, and therefore, repeat OCTs done on the day of treatment 
are important to ensure that the correct treatment is chosen 
particularly if using OCP.
For patients with small- or medium-sized holes and VMA, 
OCP is an option with significantly better results reported 
in small holes in the Phase III trials, albeit with far lower 
closure rates than surgery. For holes without VMA, vitrec-
tomy surgery is the only option but the surgeon has choices 
about whether to peel the ILM, use a short-acting gas (or air) 
or long-acting gas, whether to advice the patient to posture 
face down or combine the surgery with phacoemulsification. 
The choice of treatment is summarized in Table 7. Many 
of the studies on posturing and gas choice were carried out 
combined with ILM peeling however as discussed, if not 
done, this may influence the gas and posturing requirement. 
It is also worth reiterating that patient-specific factors and 
patient choice will influence the actual treatment decided 
Table 7 Summary treatment choice based on iMH characteristics
Focal VMA present No VMA present






250–400 µm vitrectomy + peel
Short-acting gas










Stage 4 NA vitrectomy + peel
Long- or short-acting gas
Posture based on size 
Abbreviations: iMH, idiopathic macular hole; vMA, vitreomacular attachment; 
OCP, ocriplasmin; NA, not applicable.
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upon. Adjuvants, such as platelets and transforming growth 
factor beta 2, and other surgical techniques, such as retinal 
relieving incisions and ILM flaps, are generally reserved for 
revision cases and beyond the scope of this guidance.
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